1.A Case of BOOP Developed during Bucillamine Treatment for Rheumatoid.
Young Ho LEE ; Ye Ree KIM ; Jong Dae JI ; Jae Jeong SHIM ; Kyung Ho KANG ; Ju Han LEE ; Han Kyeom KIM ; Gwan Gyu SONG
The Korean Journal of Internal Medicine 2001;16(1):36-39
We describe a patient with rheumatoid arthritis(RA) who developed bronchiolitis obliterans organizing pneumonia(BOOP) during the treatment of bucillamine. A 51 year-old man was admitted to the hospital for an abnormal shadow on his chest radiogragh. He had been diagnosed as having RA 3 years previously and had been receiving 200 mg of bucillamine for 21 months. Two months prior to admission, he presented with a cough and his chest X-ray showed opacities in both lower lungs. He was treated with antibiotics for 2 months after the development of cough and lesions on the chest X-ray, but the symptoms and lung lesions became more aggravated. On admission, an HRCT revealed airspace consolidations in the subpleural space of both basal lungs and a CT-guided fine needle aspiration biopsy showed Masson's body filling air space, interstitial infiltration of acute and chronic inflammatory cells and type II cell hyperplasia, consistent with BOOP. Bucillamine was stopped and 50 mg of prednisolone was administered. His symptoms and infiltrations on the chest X-ray resolved. We suggest that bucillamine should be considered as a drug possibly associated with BOOP.
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects*
;
Arthritis, Rheumatoid/drug therapy*
;
Biopsy, Needle
;
Bronchiolitis Obliterans Organizing Pneumonia/diagnosis*
;
Bronchiolitis Obliterans Organizing Pneumonia/chemically induced*
;
Case Report
;
Cysteine/therapeutic use
;
Cysteine/analogs & derivatives
;
Cysteine/adverse effects*
;
Follow-Up Studies
;
Human
;
Male
;
Middle Age
;
Radiography, Thoracic
;
Risk Assessment
;
Tomography, X-Ray Computed
2.Bucillamine-Induced Pemphigus Vulgaris in a Patient with Rheumatoid Arthritis and Polymyositis Overlap Syndrome.
Jin Wuk HUR ; Chang Woo LEE ; Dae Hyun YOO
Journal of Korean Medical Science 2006;21(3):585-587
Bucillamine is a disease modifying anti-rheumatic drug, structurally similar to D-penicillamine. Although D-penicillamine-induced pemphigus has been not infrequently demonstrated, pemphigus associated with bucillamine was rarely reported. We describe a patient complicating pemphigus vulgaris after bucillamine treatment in rheumatoid arthritis (RA) and polymyositis (PM) overlap syndrome. PM and RA overlap syndrome was diagnosed three years ago and bucillamine was administrated for 20 months. Skin lesions including erythematous flaccid blisters on her chest, axillae, and back were occurred and were compatible with pemphigus vulgaris by typical pathology. Withdrawal from bucillamine and prednisolone treatment made rapid improvement of pemphigus lesions.
Syndrome
;
Skin/pathology
;
Polymyositis/*complications/*drug therapy
;
Pemphigus/*chemically induced/*pathology
;
Middle Aged
;
Humans
;
Female
;
Cysteine/adverse effects/*analogs & derivatives
;
Biopsy
;
Arthritis, Rheumatoid/*complications/*drug therapy
;
Arthritis
;
Antioxidants/*adverse effects